Abstract 107P
Background
Hepatocellular carcinoma (HCC), which comprises the majority of liver cancer was a leading cause of death worldwide. The high rate of recurrence severely hampers the long-term survival of HCC patients after hepatectomy. Early recurrence, which is mainly caused by intrahepatic dissemination, accounts for nearly 70% of all recurrent cases. Circulating tumor cells (CTC) has shown potential clinical implications. CTC was associated with the severity of microvascular invasion (mVI) in the peritumoral tissue. Patients with positive CTC have higher risk of recurrence, associate with poorer survival. However, it remains unclear whether CTC is helpful in guiding the surgical plan.
Methods
In this perspective design, retrospective study, we enrolled 60 eligible patients with resectable HCC, and Child-Pugh A liver function, preoperative CTC detection was positive between January 2021 and May 2022. Thirty patients underwent anatomical resection (AR) and 30 patients underwent non-anatomical resection (NAR), clinical outcomes including clinicopathologic characteristics, recurrence-free survival (RFS) were compared.
Results
There was no significant difference in the preoperative data and incidence of blood loss and transfusion requirements between the AR group and the NAR group, although wedge resection was mainly performed in the NAR group. No major complications occurred in either group. All patients achieved radical resection, and 25 patients (41.7%, 25/60) were mVI-positive in the pathological detection. There were17 mVI-positive in the AR group and 8 mVI-positive in the NAR group. During follow-up, recurrence was more frequent in patients treated with NAR, there was 8 (26.6%) recurrence in the NAR group and 3 (10%) recurrence in the AR group. The 1-year RFS in AR and NAR groups were 90% and 73.3% (p<0.05). Multivariate analysis showed the type of surgical treatment was an independent predictor of disease recurrence.
Conclusions
In conclusion, preoperative CTC status correlated with and predicted mVI in HCC patients. AR should be performed in CTC positive in preoperative patients for ensuring disease eradication. Based on the preliminary results, randomized controlled trials will be conducted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
This research supported by Sanming Project of Medicine in Shenzhen (No.SZSM202011010).
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
88P - Sintilimab plus anlotinib as second-line therapy for metastatic or recurrent gallbladder carcinoma (GBC): A single-arm, phase II study
Presenter: Qingbao Cheng
Session: Poster viewing 02
89P - Radiotherapy followed by camrelizumab for unresectable biliary tract cancer: A phase II clinical trial
Presenter: Zhenwei Peng
Session: Poster viewing 02
90P - Feasibility of using tumor-informed circulating tumor DNA (ctDNA)-based testing for patients with anal squamous cell carcinoma
Presenter: Georges Azzi
Session: Poster viewing 02
92P - Safety of liver resection following atezolizumab plus bevacizumab treatment in hepatocellular carcinoma (HCC) patients with macrovascular invasion: A pre-specified analysis of the TALENTop study
Presenter: Huichuan Sun
Session: Poster viewing 02
93P - Outcomes by disease status in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study
Presenter: Takuji Okusaka
Session: Poster viewing 02
94P - The treatment burden of neoadjuvant carboplatin/paclitaxel versus 5-fluorouracil/cisplatin in combination with radiotherapy for patients with esophageal cancer
Presenter: Chun-Ling Chi
Session: Poster viewing 02
95P - Additional survival follow-up of TACTICS-L: Transcatheter arterial chemoembolization therapy (TACE) in combination strategy with lenvatinib in (LEN) patients with unresectable hepatocellular carcinoma in Japan
Presenter: Yoshitaka Inaba
Session: Poster viewing 02
96P - Preoperative chemotherapy flot vs dox in patients of locally advanced gastric adenocarcinoma
Presenter: POORNIMA DEVI UTHAYAKUMAR
Session: Poster viewing 02
97P - BEAR study: A single-arm, phase II trial of BI-754091 and afatinib for refractory esophageal squamous cell carcinoma
Presenter: Nai-Jung Chiang
Session: Poster viewing 02